0
0
GENEVA – In a milestone that is reshaping the scientific understanding of HIV, a man known as the “Geneva patient” has remained in treatment-free remission for nearly three years following a stem cell transplant. While he is the sixth person to achieve long-term remission after such a procedure, his case is a scientific outlier: he is the first to do so without receiving donor cells that possess a rare, HIV-resistant genetic mutation.
The findings, recently published in the journal Nature Medicine, suggest that the mechanisms required to clear HIV from the body may be more diverse than previously thought. For decades, researchers believed that a specific genetic “lock”—the CCR5-delta 32 mutation—was essential for a transplant to result in a cure. The Geneva patient’s success challenges this dogma, offering a glimmer of hope for new therapeutic strategies that do not rely on rare genetic matches.
A New Chapter in HIV Research
The Geneva patient, a man in his early 50s who has lived with HIV since 1990, underwent a stem cell transplant in July 2018 to treat a particularly aggressive form of leukemia. In the five previous cases of HIV remission—including the well-known “Berlin” and “London” patients—doctors sought out donors who carried two copies of the CCR5-delta 32 mutation. This mutation prevents the most common strains of HIV from entering human immune cells.
However, no such donor could be found for the Geneva patient. Instead, he received “wild-type” stem cells—cells that are theoretically susceptible to HIV infection.
“This case is an extraordinary proof of concept,” says Dr. Asier Sáez-Cirión, Head of the Viral Reservoirs and Immune Control Unit at the Institut Pasteur and lead author of the study. “It shows us that HIV remission is possible even without the protective mutation, suggesting there are other forces at work that can eliminate the viral reservoir.”
The “Stealth” Factors Behind the Cure
If the donor cells were not inherently resistant to the virus, why has the HIV not returned? Researchers are investigating several key factors that likely worked in concert:
-
Graft-versus-Host Effect: After the transplant, the donor’s new immune cells may have recognized the patient’s original, HIV-infected cells as “foreign” and systematically destroyed them. This “cleansing” process, known as graft-versus-host disease (GvHD), may have effectively wiped out the “reservoirs”—the hidden pockets of virus that typically cause HIV to rebound when medication is stopped.
-
Ruxolitinib Treatment: To manage his GvHD, the patient was treated with ruxolitinib, an immunosuppressive drug. Laboratory studies have suggested that ruxolitinib may inhibit HIV’s ability to replicate and persist in the body’s cells, potentially acting as an unintended “shield” during the critical post-transplant window.
-
Complete Chimerism: Within a month of the transplant, 100% of the patient’s blood cells were replaced by donor cells. This rapid and total replacement may have left the virus with no place to hide.
The Numbers and the Reality
While the Geneva patient stopped his antiretroviral therapy (ART) in November 2021 and remains undetectable today, the procedure itself remains a high-risk, last-resort treatment for cancer.
“We must be very clear: stem cell transplants are not a scalable cure for the 39 million people living with HIV worldwide,” explains Dr. Alexandra Calmy, Director of the HIV/AIDS Unit at Geneva University Hospitals. “The mortality risk associated with the procedure is significant. However, every patient like this provides a roadmap. If we can understand how his body cleared the virus, we can try to replicate that process using safer methods, such as gene therapy or new drug combinations.”
Limitations and the Road Ahead
Medical history is marked by “Boston patients”—two individuals who also received wild-type transplants but saw their HIV return after three and eight months, respectively. The Geneva patient has already surpassed these timelines significantly, but scientists remain cautious.
“We cannot yet use the word ‘cured’ with absolute certainty,” notes Dr. Sharon Lewin, President of the International AIDS Society. “As we learned from the Boston cases, even a single remaining infected cell can lead to a viral rebound. This individual will need to be monitored for years to come.”
The implications for the public are subtle but profound. This case confirms that the “viral reservoir”—the final frontier in HIV research—is not invincible. It also broadens the potential donor pool for HIV-positive cancer patients who require bone marrow transplants, as they may no longer be restricted to the 1% of the population carrying the CCR5-delta 32 mutation.
Summary of Key Findings
-
The Patient: A man in his 50s, HIV-positive since 1990, in remission for 32+ months without ART.
-
The Difference: Unlike previous cases, his donor lacked the HIV-resistant CCR5 mutation.
-
The Mechanism: Success is attributed to an aggressive immune response from the donor cells and the use of specific anti-inflammatory medication.
-
The Impact: Opens new avenues for research into “functional cures” that don’t require rare genetics.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
Study Citation:
Sáez-Cirión, A., Mamez, AC., Avettand-Fenoel, V. et al. Sustained HIV remission after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells. Nature Medicine (2024). DOI: 10.1038/s41591-024-03277-z
